Mar. 9 at 5:41 PM
$LEXX The most logical profiles for a hypertension partnership would be:
$JNJ
$NVS
$PFE
Any cardiovascular partnership would validate Dehydratech as a platform.
That would change how pharma views the entire technology stack - including GLP-1, peptides, antivirals and other molecules.
Many assume Lexaria’s first partnership will come from GLP-1 obesity drugs, but hypertension may actually be the faster path. CBD already has extensive human safety data, hypertension trials are smaller and cheaper than obesity studies, and the market exceeds a billion patients globally. Positioned as a delivery enhancement, it could follow a simpler regulatory path. Pharma typically looks for three things before partnering: human efficacy, safety, and strong IP. Lexaria appears to have all three through its hypertension studies, safety results, and expanding U.S. and European patents—putting it near the typical partnering threshold.
🔥 💰
#glp1 #hypertension
